Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels
Mounjaro (tirzepatide 15 mg) : In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks
doi: 10.3389/fphar.2026.1805842 Received 06 February 2026 Revised 30 March 2026 Accepted 06 April 2026 Published 29 April 2026 Volume 17 - 2026 Edited by Brian J Piper, Center for Pharmacy Innovation and Outcomes, United States Reviewed by Kenneth McCall, Binghamton University, United States Santenna Chenchula, All India Institute of Medical Sciences, India Youssef Soliman, Wright State University, United States Updates Copyright 2026 Zinzi, Gaio, Ruggiero, Mascolo, Riemma, Cipriani, Laino, Berrino, Rossi and Capuano
This research-backed guide explains why semaglutide-related weight gain happens, summarizes the best evidence, and gives you a practical plan to use with your care team